Identifying carriers of type 2N von Willebrand disease: Procedures and significance

被引:25
作者
Casonato, A. [1 ]
Pontara, E. [1 ]
Sartorello, F. [1 ]
Cattini, M. G. [1 ]
Perutelli, P. [1 ]
Bertomoro, A. [1 ]
Gallinaro, L. [1 ]
Pagnan, A. [1 ]
机构
[1] Univ Padua, Sch Med, Dept Med & Surg Sci, Chair Internal Med 2, Padua, Italy
关键词
VWF; FVIII; type 2N VWD; VWF : FVIIIB; VWF : FVIIB ratio; FACTOR-VIII-BINDING; VONWILLEBRAND-FACTOR; HEMOPHILIA-A; RISTOCETIN COFACTOR; FACTOR GENE; DIAGNOSIS; VARIANT; MUTATIONS; CAPACITY; DOMAIN;
D O I
10.1177/1076029606299000
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The defective FVIII carrier function of von Willebrand factor (VWF) identifies type 2N von Willebrand disease (VWD), a variant with a pattern resembling hemophilia A. Type 2N characterization is based on the evaluation of the capacity of VWF to bind exogenous FVIII (VWF:FVIIIB). Here we report on a retrospective evaluation of hemostatic laboratory parameters most useful in detecting type 2N carriers. The diagnostic capacity of aPTT, FVIII, VWF:Ag, FVIII/VWF:Ag ratio, VWF:FVIIIB and VWF:FVIIIB/VWF:Ag ratio was evaluated in 21 type 2N VWD carriers. Twenty subjects were heterozygous for the R854Q mutation, one was heterozygous for the R760C missense mutation, which interferes with cleavage of the VWF propeptide. We found that prolongation of aPTT and decrease in FVIII and FVIII/VWF:Ag ratio were not frequent findings in type 2N carriers. The same was true for VWF:FVIIIB which was not always abnormal. on the contrary, VWF:FVIIIB/VWF:Ag ratio was always defective and its values were not related with FVIII and FVIII/VWF:Ag ratio or influenced by plasma VWF concentration. Given these results, we attribute the greatest significance to VWF:FVIIIB/VWF:Ag ratio in the diagnosis of type 2N defects, and only search for type 2N mutations, to validate the diagnosis, if the ratio proves abnormal.
引用
收藏
页码:194 / 200
页数:7
相关论文
共 25 条
  • [1] Two novel type 2N von Willebrand disease-causing mutations that result in defective factor VIII binding, multimerization, and secretion of von Willebrand factor
    Allen, S
    Abuzenadah, AM
    Blagg, JL
    Hinks, J
    Nesbitt, IM
    Goodeve, AC
    Gursel, T
    Ingerslev, J
    Peake, IR
    Daly, ME
    [J]. BLOOD, 2000, 95 (06) : 2000 - 2007
  • [2] Binding of factor VIII to von Willebrand factor is enabled by cleavage of the von Willebrand factor propeptide and enhanced by formation of disulfide-linked multimers
    Bendetowicz, AV
    Morris, JA
    Wise, RJ
    Gilbert, GE
    Kaufman, RJ
    [J]. BLOOD, 1998, 92 (02) : 529 - 538
  • [3] An Arg760Cys mutation in the consensus sequence of the von Willebrand factor propeptide cleavage site is responsible for a new von Willebrand disease variant
    Casonato, A
    Sartorello, F
    Cattini, MG
    Pontara, E
    Soldera, C
    Bertomoro, A
    Girolami, A
    [J]. BLOOD, 2003, 101 (01) : 151 - 156
  • [4] Casonato A, 2001, HAEMATOLOGICA, V86, P1110
  • [5] Von Willebrand factor collagen binding activity in the diagnosis of von Willebrand disease: an alternative to ristocetin co-factor activity?
    Casonato, A
    Pontara, E
    Bertomoro, A
    Sartorello, F
    Cattini, MG
    Girolami, A
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2001, 112 (03) : 578 - 583
  • [6] Casonato A, 1998, BRIT J HAEMATOL, V103, P39
  • [7] The evaluation of factor VIII binding activity of von willebrand factor by means of an ELISA method - Significance and practical implications
    Casonato, A
    Pontara, E
    Zerbinati, P
    Zucchetto, A
    Girolami, A
    [J]. AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1998, 109 (03) : 347 - 352
  • [8] RECESSIVE INHERITANCE OF VONWILLEBRANDS DISEASE TYPE-I
    EIKENBOOM, JCJ
    REITSMA, PH
    PEERLINCK, KMJ
    BRIET, E
    [J]. LANCET, 1993, 341 (8851) : 982 - 986
  • [9] FAVALORO EJ, 1995, AM J CLIN PATHOL, V104, P264
  • [10] FAY PJ, 1991, J BIOL CHEM, V266, P2172